The use of BRAF-inhibitor monotherapy (e.g., dabrafenib) in advanced BRAFV600E/K mutant melanoma is associated with the development of secondary skin neoplasms (such as cutaneous squamous cell carcinomas and keratoacanthomas). This evidence concerns the gene BRAF and keratoacanthoma.